

GOVERNMENT OF MIZORAM  
HEALTH & FAMILY WELFARE DEPARTMENT  
MIZORAM SECRETARIAT BUILDING, MINECO, KHATLA, AIZAWL-796001

NOTIFICATION

*Dated Aizawl, the 18<sup>th</sup> October, 2021*

**No.D.33011/21/2021-HFW(nCOV)/Pt.I/9:** Following the recommendations of the State Level Expert Team for Covid-19 Management, the competent authority hereby notifies the following guidelines for isolation and treatment of Covid-19 patients in the State of Mizoram in addition to the existing guidelines for management of Covid-19, with immediate effect and until further order:

**1. Isolation and treatment of Covid-19 patient:**

- 1.1 In addition to the standing protocol/ guidelines for management of Covid-19, the following directions shall be strictly followed for isolation and treatment of Covid-19 patients:-
- 1.2 Persons tested as Covid-19 positive but without any symptom (***asymptomatic***) or with ***mild symptoms*** should be **isolated at home** by strictly following the **SOP for Home Isolation** issued by the Government.
- 1.3 If the Covid-19 patient is isolated in any Covid care facility, his/ her family members should follow the **SOP for Contact Tracing dated 28.09.2021**.
- 1.4 **Covid-19 positive patients with any of the following symptoms should be shifted to Dedicated Covid Health Centre (DCHC) or Dedicated Covid Hospital (DCH):**
  - (1) Persistent high fever with temperature of  $\geq 100.4^{\circ}\text{F}$  for  $\geq 5$  days; or
  - (2) Worsening cough; or
  - (3) Shortness of breath with  $\text{SpO}_2 < 94\%$  in room air (6-minute walk – if  $\text{SpO}_2$  drops by 3 – 5% from baseline, Respiratory rate  $\geq 24/\text{min}$ ; or
  - (4) Persistent diarrhoea  $\geq 5$  days; or
  - (5) Hemodynamic Instability (Hypertensive emergency/ urgency, Shock, failure); or
  - (6) Altered Sensorium, Severe chest pain.

**2. Administration of Monoclonal Antibody Cocktail for high-risk Covid-19 patient:**

**2.1 Patient Selection and Treatment Initiation:**

Though being unapproved products, casirivimab and imdevimab may be administered for the treatment of mild to moderate Covid-19 in adults and paediatric patients (**12 years of age and older, weighing at least 40 Kgs**) with positive results of direct SARS COV-2 viral testing and **who are high risk** for progressing to severe Covid-19 and/or hospitalisation.

**High risk** is defined as patients who meet at least one of the following criteria:-

- (a) Have a body mass index (BMI)  $\geq 35$ .
- (b) Have chronic kidney disease.

- (c) Have diabetes.
- (d) Have immunosuppressive disease.
- (e) Are currently receiving immunosuppressive treatment.
- (f) Are  $\geq 65$  years of age.
- (g) Are  $\geq 55$  years of age and have –
  - i. cardiovascular disease, OR
  - ii. hypertension, OR
  - iii. chronic obstructive pulmonary disease/ other chronic respiratory disease.
- (h) Are **12 – 17 years of age and have–**
  - i. BMI  $\geq 85^{\text{th}}$  percentile for their age and gender based on CDC growth charts (available at [https://www.cdc.gov/growthcharts/clinical\\_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm) OR
  - ii. Sickle cell disease; OR
  - iii. Congenital or acquired heart disease, OR
  - iv. Neurodevelopmental disorder, eg. cerebral palsy OR gastrostomy OR positive pressure ventilation (not related to Covid-19, OR
  - v. Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.

## 2.2 **Dosage:**

The dosage in adults and in paediatric patients (12 years of age and older weighing at least 40 Kgs) is **1200 mg of casirivimab and 1200 mg of imdevimab** administered together as a single intravenous infusion over at least **60 minutes**. Casirivimab and imdevimab solution must be diluted prior to administration. Casirivimab and imdevimab should be given together as soon as possible after positive results of direct SARS COV-2 viral testing and **within 10 days from onset of the symptom**.

## 3. **Availability of Covid-19 drugs:**

All Officials of the Health & Family Welfare Department, under whose jurisdiction Covid care facilities are set up, shall ensure that Tocilizumab and other essential Covid-19 drugs are available in sufficient quantities for use at all levels of Covid care facilities under their respective jurisdictions, following the **Guidelines for Buffer Stock Management of Covid-19 Drugs** issued by the Ministry of Health & Family Welfare, Govt. of India, dated 29.06.2021.

## 4. **Protection of high-risk groups:**

- 4.1 All Chief Medical Officers shall identify high risk groups, such as, **pregnant women, elderly in the age group of >60 years, and persons with comorbidity**, and monitor them closely for any occurrence of Covid-19 infection, and ensure administration of prescribed drugs.



- 4.2 All the families/ households of person(s) belonging to high risk groups shall ensure the safety of such high-risk member of the family by strictly following the CAB within their respective homes.

*Ram 18/10/21*

**(R. LALRAMNGHAKA)**

Secretary to the Government of Mizoram  
Health & Family Welfare Department.

**No.D.33011/21/2021-HFW(nCOV)/Pt.I/9 : Dated Aizawl, the 18<sup>th</sup> Oct., 2021.**

Copy to:-

1. Secretary to the Governor, Govt. of Mizoram.
2. P.S to Chief Minister, Govt. of Mizoram.
3. P.S. to Deputy Chief Minister, Govt. of Mizoram.
4. P.S to Speaker, Ministers, Deputy Speaker, Ministers of State, Deputy Govt. Chief Whip, Vice Chairman, Lunglei HPC, Vice Chairman, State Planning Board.
5. P.S to MLA & Vice Chairman, H&FW Board.
6. Sr. PPS to Chief Secretary, Government of Mizoram.
7. PPS to Secretary, Health & Family Welfare Department.
8. PPS to Secretary, Home/DM&R Department
9. All Administrative Heads of Department, Govt. of Mizoram.
10. All Heads of Departments, Govt. of Mizoram
11. All Deputy Commissioners, Mizoram.
12. Principal Director, Health & Family Welfare Department.
13. Director, Health services.
14. Director, Hospital & Medical Education.
15. Director, Zoram Medical College, Falkawn.
16. Director, Information & Public Relations for wide circulation.
17. Mission Director, NHM.
18. All Medical Superintendents
19. All Chief Medical Officers
20. Controller, Printing & Stationeries with five (5) spare copies for publication in the Official Gazette.
21. Web Manager, IT Section, Directorate of Health Services.
22. Guard file.

*Josephine 4/10/21*

**(JOSEPHINE ZONUNSANGI)**

Under Secretary to the Govt. of Mizoram,  
Health & Family Welfare Department